160 related articles for article (PubMed ID: 38352877)
41. Efficient Colon Cancer Immunogene Therapy Through Co-Delivery of IL-22BP mRNA and Tumor Cell Lysate by CLSV Nanoparticles.
Huang J; Wang K; Fu X; Zhu M; Chen X; Gao Y; Ma P; Duan X; Men K
Int J Nanomedicine; 2023; 18():8059-8075. PubMed ID: 38164262
[TBL] [Abstract][Full Text] [Related]
42. Therapy implications of the role of interleukin-2 in cancer.
Lissoni P
Expert Rev Clin Immunol; 2017 May; 13(5):491-498. PubMed ID: 27782752
[TBL] [Abstract][Full Text] [Related]
43. Interleukin-2: Old and New Approaches to Enhance Immune-Therapeutic Efficacy.
Dhupkar P; Gordon N
Adv Exp Med Biol; 2017; 995():33-51. PubMed ID: 28321811
[TBL] [Abstract][Full Text] [Related]
44. The CDK4/6 inhibitor palbociclib synergizes with irinotecan to promote colorectal cancer cell death under hypoxia.
Zhang J; Zhou L; Zhao S; Dicker DT; El-Deiry WS
Cell Cycle; 2017 Jun; 16(12):1193-1200. PubMed ID: 28486050
[TBL] [Abstract][Full Text] [Related]
45. Nano-Self Assembled Photosensitizer Composed of Methoxy Poly(ethylene glycol)-Conjugated Chlorin e6 for Enhanced Photosensing of HCT116 Cells.
Chung CW; Choi CW; Jeong YI; Kang DH
J Nanosci Nanotechnol; 2016 Feb; 16(2):1379-83. PubMed ID: 27433590
[TBL] [Abstract][Full Text] [Related]
46. Nanoparticle delivery of recombinant IL-2 (BALLkine-2) achieves durable tumor control with less systemic adverse effects in cancer immunotherapy.
Kim J; Kang S; Kim KW; Heo MG; Park DI; Lee JH; Lim NJ; Min DH; Won C
Biomaterials; 2022 Jan; 280():121257. PubMed ID: 34839122
[TBL] [Abstract][Full Text] [Related]
47. Inhibition of cyclin-dependent kinase 4 as a potential therapeutic strategy for treatment of synovial sarcoma.
Li X; Seebacher NA; Garbutt C; Ma H; Gao P; Xiao T; Hornicek FJ; Duan Z
Cell Death Dis; 2018 May; 9(5):446. PubMed ID: 29670090
[TBL] [Abstract][Full Text] [Related]
48. INBRX-120, a CD8α-targeted detuned IL-2 that selectively expands and activates tumoricidal effector cells for safe and durable in vivo responses.
Sulzmaier FJ; Kern N; Ahn SJ; Polovina A; Ho J; Hussain A; Cyprus G; Macedo C; Pandit R; Crago W; Rowell E; Timmer JC; Eckelman BP
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36653071
[TBL] [Abstract][Full Text] [Related]
49. Polymer nanoparticles for enhanced immune response: combined delivery of tumor antigen and small interference RNA for immunosuppressive gene to dendritic cells.
Heo MB; Cho MY; Lim YT
Acta Biomater; 2014 May; 10(5):2169-76. PubMed ID: 24394635
[TBL] [Abstract][Full Text] [Related]
50. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
Hadinoto K; Sundaresan A; Cheow WS
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180
[TBL] [Abstract][Full Text] [Related]
51. A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti-PD-(L)1 and Anti-CTLA-4 in Preclinical Models.
Willingham SB; Ho PY; Hotson A; Hill C; Piccione EC; Hsieh J; Liu L; Buggy JJ; McCaffery I; Miller RA
Cancer Immunol Res; 2018 Oct; 6(10):1136-1149. PubMed ID: 30131376
[TBL] [Abstract][Full Text] [Related]
52. Combined therapy with methotrexate nanoconjugate and dendritic cells with downregulated IL-10R expression modulates the tumor microenvironment and enhances the systemic anti-tumor immune response in MC38 murine colon carcinoma.
Szczygieł A; Węgierek-Ciura K; Wróblewska A; Mierzejewska J; Rossowska J; Szermer-Olearnik B; Świtalska M; Anger-Góra N; Goszczyński TM; Pajtasz-Piasecka E
Front Immunol; 2023; 14():1155377. PubMed ID: 37033926
[TBL] [Abstract][Full Text] [Related]
53. Poly(L-Glutamic Acid)-Drug Conjugates for Chemo- and Photodynamic Combination Therapy.
Yu H; Bao Y; Xu C; Chen L; Tang Z
Macromol Biosci; 2021 Jan; 21(1):e2000192. PubMed ID: 33043592
[TBL] [Abstract][Full Text] [Related]
54. Polymer-polymer conjugation to fabricate multi-block polymer as novel drug carriers: poly(lactic acid)-poly(ethylene glycol)-poly(L-lysine) to enhance paclitaxel target delivery.
Liu Y; Liu C; Li M; Liu F; Feng L; Zhang L; Zhang N
J Biomed Nanotechnol; 2014 Jun; 10(6):948-58. PubMed ID: 24749390
[TBL] [Abstract][Full Text] [Related]
55. Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast Cancer.
Whittle JR; Vaillant F; Surgenor E; Policheni AN; Giner G; Capaldo BD; Chen HR; Liu HK; Dekkers JF; Sachs N; Clevers H; Fellowes A; Green T; Xu H; Fox SB; Herold MJ; Smyth GK; Gray DHD; Visvader JE; Lindeman GJ
Clin Cancer Res; 2020 Aug; 26(15):4120-4134. PubMed ID: 32245900
[TBL] [Abstract][Full Text] [Related]
56. Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer.
De Angelis C; Fu X; Cataldo ML; Nardone A; Pereira R; Veeraraghavan J; Nanda S; Qin L; Sethunath V; Wang T; Hilsenbeck SG; Benelli M; Migliaccio I; Guarducci C; Malorni L; Litchfield LM; Liu J; Donaldson J; Selenica P; Brown DN; Weigelt B; Reis-Filho JS; Park BH; Hurvitz SA; Slamon DJ; Rimawi MF; Jansen VM; Jeselsohn R; Osborne CK; Schiff R
Clin Cancer Res; 2021 Sep; 27(17):4870-4882. PubMed ID: 33536276
[TBL] [Abstract][Full Text] [Related]
57. Pro-inflammatory chitosan/poly(γ-glutamic acid) nanoparticles modulate human antigen-presenting cells phenotype and revert their pro-invasive capacity.
Castro F; Pinto ML; Silva AM; Pereira CL; Teixeira GQ; Gomez-Lazaro M; Santos SG; Barbosa MA; Gonçalves RM; Oliveira MJ
Acta Biomater; 2017 Nov; 63():96-109. PubMed ID: 28919508
[TBL] [Abstract][Full Text] [Related]
58. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
59. Advanced application of stimuli-responsive drug delivery system for inflammatory arthritis treatment.
Zhang M; Hu W; Cai C; Wu Y; Li J; Dong S
Mater Today Bio; 2022 Mar; 14():100223. PubMed ID: 35243298
[TBL] [Abstract][Full Text] [Related]
60. Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity.
Kwong B; Gai SA; Elkhader J; Wittrup KD; Irvine DJ
Cancer Res; 2013 Mar; 73(5):1547-58. PubMed ID: 23436794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
